Motivation: Expression profile of normal tissue is primary source to find genes showing aberrant expression pattern specific in matched cancer tissue, but sample number of normal control in public gene expression repositories is disproportionally small compared to cancer and scattered in several datasets. Results: We built oncopression by integrating several datasets into one large dataset for comprehensive analysis about 25 types of human cancers including 20 640 cancer samples and 6801 normal control profiles. Expression profiles in cancers can be directly compared to normal tissue counterparts. Validity of the integration was tested using immunohistochemical staining results and principal component analysis. We have utilized the pre-release version of oncopression to identify cancer-specific genes in several studies.
Introduction
It is becoming easier to profile gene expression at system levels, and vast amount of such profile results continue to be deposited in public database such as Gene Expression Omnibus (GEO) (Barrett et al., 2013) , ArrayExpress (AE) (Parkinson et al., 2007) and International Cancer Genome Consortium (ICGC) (Zhang et al., 2011) . Besides the data portals, there are services such as ExpressionAtlas (Petryszak et al., 2014) , cBioPortal (Gao et al., 2013) , ExAc Browser (Lek et al., 2016) and oncomine (Rhodes et al., 2004) providing analysis pipeline and visualization for several types of profile data. One can easily explore molecular features in cancer such as mutation rate, expression state, copy number variation, etc. with web-interface of the data portals. The main caveat of these databases and services, however, is the absence or inadequate number of matched control samples for direct comparison.
Normal sample can be used at initial stage of cancer research by providing clue for abnormal expression pattern of genes in cancer compared to normal. Nonetheless, it is more difficult to make analytical samples of normal subjects than those of patients, especially in case of malignant brain cancers. This is mainly due to unbalanced sample numbers such that none or small number of normal and large number of cancer samples in many datasets. To overcome this limitation, we collected several small number of normal samples distributed in several datasets and integrated them into single dataset using single sample estimate normalization method SCAN.UPC (Piccolo et al., 2013) which produces absolute expression value from 0.0 to 1.0 based on Gaussian mixture model of expression profiles.
Materials and methods
Expression profiles in GEO and AE of cancer patients were collected using semi-automated annotation curation environment. We collected normal samples in all datasets regardless of cancer- Applications Note association because SCAN.UPC normalization makes it possible to compare expression profiles across different datasets. Some of normal samples are matched ones from same patients, and in this case this information is provided as sample configuration file in oncopression website. We collected datasets with Affymetrix Human Genome U133 Plus 2.0 (GPL570 in GEO and A-AFFY-44 in AE) because samples of this platform are most abundant in GEO. Annotations in each GSM file of GEO and sdrf file of AE were carefully checked. Cancer samples were further divided by histological classification if available in the annotation. If there are sample information useful for sub-grouping such as tumor grade, stage and mutation states of specific genes, then samples are further subgrouped by the corresponding information.
All raw CEL files of selected samples in collection step were downloaded from GEO and AE. CEL files were normalized by SCAN.UPC package of BioConductor of R with default option. To make single gene expression value with several probes for the same gene, we used probe summary package from BrainArray version 17.0 of Entrez GENE ID form. Duplicated samples were found by gene expression Euclidean distance <1e-20 and only one of them is retained.
To check validity of the integration, we performed principal component analysis (PCA) and tested distribution of samples in 2-dimension (2D) by 2D two-sample Kolmogorov-Smirnov (2D-KS) test. To do this, we made two expression matrix files (normal/cancer) with all tissue data. For each matrix file, one thousand genes with the largest stdev/ave value were selected for PCA projection. For 1000Â N matrix, where N is 6081 for normal and 20 640 for cancer, PC1 and PC2 coefficients were found. All samples were projected with the coefficients into 2D-space.
Results

Sample statistics of oncopression
Oncopression contains 6081 normal and 20 640 cancer expression profiles from 269 and 389 datasets, respectively (Supplementary  Table S1 ) for 25 types of tissues, and this can be accessed as webservice (www.oncopression.com). Cancers are further categorized according to features found in annotation such as tumor grade, tumor stage, mutation type, etc. Sub-group specific expression pattern can be explored by clicking each of cancer tissue in oncopression webinterface.
Validity of dataset integration
We checked validity and consistency of integration of datasets normalized by SCAN.UPC. First, we compared UPC value of three important cancer-related hormone receptors for estrogen, progesterogen and her2 with their immunohistochemical staining (IHC) results available in annotation in breast cancer. As seen in Supplementary Figure S1 , UPC value of the receptors are compatible with IHC information. Next, we performed PCA projection to illustrate tissue specific distribution pattern in 2D-space with the major two components, and performed 2DKS test to check if samples of different tissues have similar distribution in 2D-space or not. For both normal and cancer data, samples are closely clustered according to their tissue type (Fig. 1A and B) , and most of tissues are turned out distributed different from the others by 2DKS test (Supplementary Table S2 ). Lastly, we found that gene expression correlation between same type of datasets are larger than that of different types of datasets (Supplementary Fig S2) .
Use of oncopression in cancer research
Oncopression itself is focused on microarray-based gene expression profiles for normal and cancer. Oncopression provides graphical comparison results between normal and cancer with student t-test statistics and classification performance as area under curve of receiver-operating curve (AUC of ROC) for a gene queried via webinterface. User can query single gene expression pattern, or download whole expression matrices for all tissues and curated sample annotation files formatted suitable for computational process. As one important issue we remind users of oncopression to that there can be bias in results made from different studies caused by uncontrolled variables.
We provide simple example of oncopression usage. To be promising drug target for over-expressed gene in cancer, the gene should be marginally expressed in other normal tissues as well as in matched normal tissue. This kind of genes can be found with oncopression as shown in Figure 1C because oncopression provides expression for several normal tissues.
Pre-release version of oncopression has been used in several cancer-related researches (Cha et al., 2016; Lee et al., 2015 Lee et al., , 2016a Park et al., 2015 Park et al., , 2016 . We recapitulated the researches in supplementary data (Supplementary Table S3 ). Briefly speaking, the authors of the researches focused on cancer-promoting genes, therefore, they checked if genes of their interests are over-expressed in cancer compared to matched normal tissue in oncopression to proceed to experimental validation. Among several candidate genes, Lee et al. used oncopression to select the most over-expressed genes in cancer compared to matched normal tissue as promising ones with which experimental validation followed (Lee et al., 2016a, b) . 
Conclusion
We focused on cancer and made semi-automatic pipeline for sample group configuration generation. Using the pipeline, we collected 683 datasets for cancers and normal samples. As pre-release version of oncopression was successfully used in a variety of cancer-related researches, we anticipate oncopression continue contribution to cancer research.
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